Actively Recruiting
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Led by Shahid Beheshti University of Medical Sciences · Updated on 2026-02-11
50
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.
CONDITIONS
Official Title
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Estimated glomerular filtration rate (eGFR) greater than 25 cc/min
- Chronicity index less than 8
- Interstitial fibrosis and tubular atrophy (IFTA) less than 40%
- Positive Epstein-Barr virus (EBV) IgG test
You will not qualify if you...
- Active or recurrent infections
- History of malignancy unless in remission for more than 2 years with no relapse
- Abnormal liver function tests
- Platelet count less than 100,000
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nooshin Dalili
Tehran, Iran, 1666663421
Actively Recruiting
Research Team
P
PI
CONTACT
P
PI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here